Ellevest Inc’s Procept Biorobotics PRCT Stock Holding History

Ellevest Inc’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1	Closed	–	–	1802
2022 Q2	$0	Buy	+1	New	+$36	﹤0.01%	1622

Other funds holding PRCT

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Ellevest Inc's PRCT Position: Q3 2022 in Review

Ellevest Inc sold out of Procept Biorobotics (PRCT) in Q3 2022, closing a stake of 1 share.

Ellevest Inc first reported a position in PRCT in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 103 funds tracked by Wall St. Rank hold PRCT as of Q3 2022.

Ellevest Inc reported no remaining Procept Biorobotics position as of Q3 2022 after selling out during the quarter.
Ellevest Inc sold 1 Procept Biorobotics share in Q3 2022.
Ellevest Inc first reported a position in Procept Biorobotics in Q2 2022 and held it in 1 quarter.
Ellevest Inc's Procept Biorobotics position peaked at $0 in Q2 2022.
103 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2022.

Based on Ellevest Inc's 13F filing for Q3 2022, filed 2 Nov 2022.